Reading ANIP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIP free→Reading ANIP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIP free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, and risk is moderate, though the sector backdrop is a headwind. Peer multiples imply a price about 19% above where it trades (it looks cheap on this basis); the read is fair, quality intact. Key factors to watch include any potential guidance cuts after recent raises and the performance of sector bellwethers like TEVA, HLN, and ZTS. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $82.29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $82 ANIP trades at 11× p/e, below its 13× p/e peer median. Our $106 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 22% below a flat-multiple fair value, well above our forecast of about -60%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.27x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.00 → $2.01 (+0.5% / 30d). 1 raised, 5 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 88% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$123.
How much price usually moves either way.
On a bad day, this stock has moved -$276.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,866.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Cortrophin Gel is key to ANI's growth. Strong sales show demand is rising.
Confirms:Cortrophin Gel revenue grows year over year by more than 55%.
Disproves:Cortrophin Gel revenue growth is less than 55% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ANIP yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ANI Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the stockholders of the Company approved the Company’s Amended and Restated 2022 Stock Incentive Plan (the “Amended 2022 Stock Plan”). The description of the material terms of the Amended 2022 Stock Pl…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ANIP ANI Pharmaceuticals, Inc. | Above typical Show detailsSector percentile: 80 of 100 | fair | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on maximizing multi-year growth opportunities for Cortrophin Gel across various indications.
Continue to explore opportunities to expand the scope and scale of the Rare Disease business.
Maintain disciplined capital allocation with a focus on R&D and business development.
Continue to launch new Generics products, targeting 10-15 launches in 2026.
Initiate a $100 million share repurchase program authorized by the Board of Directors.
Why it matters: Changes in revenue guidance can signal shifts in business performance.
Confirms one read:Total net revenue guidance is raised above $1,140 million.
Confirms the other:Total net revenue guidance is lowered below $1,080 million.
Why it matters: New Generics products can boost revenue and support financial growth.
Confirms:ANI launches at least 10 new Generics products in 2026.
Disproves:Fewer than 10 new Generics products are launched in 2026.
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant ha…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On April 1, 2026, ANI Pharmaceuticals, Inc. (the “Company”) notified EisnerAmper LLP (“EisnerAmper”) that EisnerAmper would be dismissed as the Company’s independent registered public accounting firm. The Audit and Finance Committee of the Board of Directors of the Company (the “Audit Committee”) approved the decision to dismiss EisnerAmper, which became effective on April 1, 2026. Th…
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant ha…